Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical timolol versus oral propranolol for infantile hemangiomas
ACTRN12626000236392Phase 3Not yet recruiting
- Sponsor
- King Edward Medical University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of timolol and propranolol in Capillary Haemangioma (2 arms), sponsored by King Edward Medical University. Primary endpoint: Efficacy of topical timolol compared to oral propranolol. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
timololpropranolol
03
Conditions
Capillary Haemangioma
Beyond the preview
Go deeper on ACTRN12626000236392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000236392.